A novel cereblon modulator for targeted protein degradation

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Immunomodulatory drugs (IMiDs) target multiple myeloma by degrading IKZF1/3 via cereblon (CRBN) binding.
• The E3 ubiquitin ligase recruitment ability of IMiDs is foundational to proteolysis targeting chimera (PROTAC) technology.
• Targeted protein degradation offers a novel therapeutic strategy for various cancers.

Purpose of the Study:

• To design and synthesize a novel IMiD analog, TD-106, with enhanced CRBN modulation capabilities.
• To evaluate the efficacy of TD-106 in inducing IKZF1/3 degradation and inhibiting multiple myeloma cell proliferation in vitro and in vivo.
• To explore the potential of a TD-106-based PROTAC (TD-428) in degrading BET proteins and suppressing C-MYC transcription in prostate cancer.

Main Methods:

• Synthesis and characterization of the novel IMiD analog TD-106.
• In vitro and in vivo assays to assess IKZF1/3 degradation and anti-proliferative effects on multiple myeloma cells.
• Design and synthesis of TD-428, a PROTAC molecule linking TD-106 to a BET inhibitor (JQ1).
• Evaluation of TD-428's efficacy in degrading BET proteins and inhibiting C-MYC transcription in prostate cancer cells.

Main Results:

• TD-106 successfully induced IKZF1/3 degradation and inhibited multiple myeloma cell proliferation both in vitro and in vivo.
• The PROTAC molecule TD-428 efficiently mediated BET protein degradation in the 22Rv1 prostate cancer cells.
• TD-428 treatment led to suppressed C-MYC transcription, resulting in inhibited cell proliferation.

Conclusions:

• The novel IMiD analog TD-106 is a potent CRBN modulator with significant anti-myeloma activity.
• TD-106 serves as a valuable component for developing new targeted protein degradation strategies.
• The study demonstrates the versatility of IMiD-based PROTACs for targeting various proteins, including BET, in different cancer types.